Antitumor Antibodies Can Drive Therapeutic T Cell Responses
© 2017 Elsevier Inc. The classical view of therapeutic monoclonal antibodies (mAbs) against tumor-associated antigens (TAAs) is that their mechanism of action is dominated by signal blocking or the cytotoxicity of Fc-driven innate immune effector functions. We review here a mounting body of evidence...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier BV
2021
|
| Online Access: | https://hdl.handle.net/1721.1/134531 |
| _version_ | 1826193734940753920 |
|---|---|
| author | Wittrup, K Dane |
| author_facet | Wittrup, K Dane |
| author_sort | Wittrup, K Dane |
| collection | MIT |
| description | © 2017 Elsevier Inc. The classical view of therapeutic monoclonal antibodies (mAbs) against tumor-associated antigens (TAAs) is that their mechanism of action is dominated by signal blocking or the cytotoxicity of Fc-driven innate immune effector functions. We review here a mounting body of evidence that anti-TAA mAbs are capable of profoundly synergizing with T cell-directed immunotherapies such as checkpoint blockade and adoptive cell therapy. Two key components account for this synergy: (i) a self-vaccinal effect mediated by dendritic cells (DCs); and (ii) an inflammatory repolarization of the tumor microenvironment. Efficient exploitation of these mechanisms has tremendous therapeutic potential. |
| first_indexed | 2024-09-23T09:44:05Z |
| format | Article |
| id | mit-1721.1/134531 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T09:44:05Z |
| publishDate | 2021 |
| publisher | Elsevier BV |
| record_format | dspace |
| spelling | mit-1721.1/1345312021-10-28T04:41:09Z Antitumor Antibodies Can Drive Therapeutic T Cell Responses Wittrup, K Dane © 2017 Elsevier Inc. The classical view of therapeutic monoclonal antibodies (mAbs) against tumor-associated antigens (TAAs) is that their mechanism of action is dominated by signal blocking or the cytotoxicity of Fc-driven innate immune effector functions. We review here a mounting body of evidence that anti-TAA mAbs are capable of profoundly synergizing with T cell-directed immunotherapies such as checkpoint blockade and adoptive cell therapy. Two key components account for this synergy: (i) a self-vaccinal effect mediated by dendritic cells (DCs); and (ii) an inflammatory repolarization of the tumor microenvironment. Efficient exploitation of these mechanisms has tremendous therapeutic potential. 2021-10-27T20:05:26Z 2021-10-27T20:05:26Z 2017 2019-09-13T18:23:58Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/134531 en 10.1016/J.TRECAN.2017.07.001 Trends in Cancer Creative Commons Attribution-NonCommercial-NoDerivs License http://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf Elsevier BV PMC |
| spellingShingle | Wittrup, K Dane Antitumor Antibodies Can Drive Therapeutic T Cell Responses |
| title | Antitumor Antibodies Can Drive Therapeutic T Cell Responses |
| title_full | Antitumor Antibodies Can Drive Therapeutic T Cell Responses |
| title_fullStr | Antitumor Antibodies Can Drive Therapeutic T Cell Responses |
| title_full_unstemmed | Antitumor Antibodies Can Drive Therapeutic T Cell Responses |
| title_short | Antitumor Antibodies Can Drive Therapeutic T Cell Responses |
| title_sort | antitumor antibodies can drive therapeutic t cell responses |
| url | https://hdl.handle.net/1721.1/134531 |
| work_keys_str_mv | AT wittrupkdane antitumorantibodiescandrivetherapeutictcellresponses |